Larkspur Bioscience develops small molecule therapeutics designed to target cancer cell fitness pathways. These compounds decrease cancer cell fitness, making tumors susceptible to intrinsic and immune-mediated killing mechanisms. The company focuses on overcoming resistance limitations associated with current targeted and immune therapies.
Funding
$35.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
3BFounders
Product
Problem
Many cancer patients do not respond to existing immunotherapies due to cancer-intrinsic factors that enable tumors to evade immune detection. This is particularly true for certain molecularly defined patient populations, such as those with colorectal cancer, who do not benefit from current treatment options.
Solution
Larkspur develops novel immunotherapies that target these cancer-intrinsic factors, aiming to restore immune recognition and control of tumors. By focusing on the mechanisms within the cancer cells that allow them to escape immune surveillance, Larkspur's approach seeks to create new treatment options for patients who are not responsive to existing therapies. This strategy aims to enhance the immune response specifically in molecularly defined patient populations, offering a more targeted and effective approach to cancer immunotherapy.
Target Audience
The primary target audience includes cancer patients, particularly those with colorectal cancer and other molecularly defined patient populations, who are not responsive to existing immunotherapy treatments.
Features
- Development of immunotherapies targeting cancer-intrinsic immune evasion mechanisms.
- Focus on molecularly defined patient populations to enhance treatment efficacy.
- Aims to restore immune recognition and control of tumors.